Neurological disorders such as Alzheimer's disease, stroke, and brain cancers are difficult to
treat with current drugs as their delivery efficacy to the brain is severely hampered by the …

The history of brain drug delivery is reviewed beginning with the first demonstration, in 1914,
that a drug for syphilis, salvarsan, did not enter the brain, due to the presence of a blood …

Extracellular vesicles (EVs) are particles naturally released from cells that are delimited by a
lipid bilayer and are unable to replicate. How the EVs cross the Blood–Brain barrier (BBB) in …

The blood–brain barrier (BBB) is one of the most selective endothelial barriers. An
understanding of its cellular, morphological, and biological properties in health and disease …

The human intestinal microbiome substantially affects human health and resistance to
infections in its dynamic composition and varying release of microbial-derived metabolites …

Recent advances in biomaterials, microfabrication, microfluidics, and cell biology have led to
the development of organ-on-a-chip devices that can reproduce key functions of various …

Viruses have evolved the ability to bind and enter cells through interactions with a wide
variety of cell macromolecules. We engineered peptide-modified adeno-associated virus …

The delivery of therapeutics to the brain in an efficient, noninvasive manner continues to be
a major unmet need in the field of drug delivery. One significant impediment to brain delivery …

Organ-on-chip (OOC) systems recapitulate key biological processes and responses in vitro
exhibited by cells, tissues, and organs in vivo. Accordingly, these models of both health and …

Nanoparticle‐based therapeutic formulations are being increasingly explored for the
treatment of various ailments. Despite numerous advances, the success of nanoparticle …